Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis

Faruqui et al., Indian J. Med. Res., doi:10.4103/ijmr.IJMR_2294_20
Mar 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Retrospective 1303 health care workers finding that HCQ prophylaxis was well tolerated. 20% reported an adverse event, mostly gastrointestinal. 1.5% received treatment for adverse effects, with none requiring hospitalization.
Faruqui et al., 26 Mar 2021, peer-reviewed, 24 authors.
This PaperHCQAll
Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis
Nilima A Kshirsagar, Atiya R Faruqui, Denis Xavier, Sandhya K Kamat, Sujith J Chandy, Bikash Medhi, Raakhi K Tripathi, Yashashri C Shetty, Johnmichael Raj, Sandeep Kaushal, S Balakrishnan, Shubham Atal, Santanu K Tripathi, Dinesh K Badyal, Harihar Dikshit, Sukalyansaha Roy, Niyati Trivedi, Suparna Chatterjee, Chetna Desai, C D Tripathi, Nirmala N Rege, Pooja Gupta, R Raveendran, Rajni Kaul
Indian Journal of Medical Research, doi:10.4103/ijmr.ijmr_2294_20
Background & objectives: Hydroxychloroquine (HCQ), reported to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in in vitro studies, has been recommended for prophylaxis of COVID-19 in healthcare workers (HCWs). The objective of this study was to assess short-term adverse events (AEs) of HCQ in HCWs. Methods: This cross-sectional study among consenting HCWs taking prophylaxis and working in hospitals with COVID-19 patients used online forms to collect details of HCWs, comorbidities, prophylactic drugs used and AEs after the first dose of HCQ. Verification of dose and AEs was done by personal contact. Multivariate logistic regression analysis was done to determine the effect of age, gender and dose of HCQ on AE. Results: Of the 1303 HCWs included, 98.4 per cent (n=1282) took HCQ and 66 per cent (n=861) took 800 mg as first day's dose. Among the 19.9 per cent (n=259) reporting AEs, 1.5 per cent (n=20) took treatment for AE, none were hospitalized and three discontinued HCQ. Gastrointestinal AEs were the most common (172, 13.2%), with less in older [odds ratio (OR) 0.56, 95% confidence interval (CI) 0.35-
Financial support & sponsorship:
References
Bienvenu, Marty, Jones, Picot, Systematic review of registered trials of hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020, One Health
Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19, N Engl J Med
Chivese, Musa, Hindy, Wattary, Badran et al., A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection, medRxiv, doi:10.1101/2020.07.28.20164012
Furst, Lindsley, Baethge, Botstein, Caldwell et al., Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: A randomized, double-blind six-week trial with eighteen-week extension, Arthritis Rheum
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Liu, Li, Zhang, Kwong, Li et al., Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: A systematic review and metaanalysis, Drug Des Devel Ther
Llewelyn, Schilling, Down, but not out: Hydroxychloroquine could still have a role against COVID-19, J Pharm Health Serv Res, doi:10.1211/PJ.2020.20208233
Morgan, Patel, Dvorkina, Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus, J Clin Rheumatol
O'laughlin, Mehta, Wong, Life threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine, Case Rep Cardiol
Plaquenil®, Hydroxychloroquine Sulfate, USP
Rainsford, Parke, Clifford-Rashotte, Kean, Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases, Inflammopharmacology
Recovery Collaborative Group, Horby, Mafham, Linsell, Bell et al., Effect of hydroxychloroquine in hospitalized patients with COVID-19, N Engl J Med
Sharma, Mesinkovska, Paravar, Characterizing the adverse dermatologic effects of hydroxychloroquine: A systematic review, J Am Acad Dermatol
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit